Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2018

Open Access 01-12-2018 | Research article

Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial

Authors: Niikee Schoendorfer, Nita Sharp, Tracey Seipel, Alexander G. Schauss, Kiran D. K. Ahuja

Published in: BMC Complementary Medicine and Therapies | Issue 1/2018

Login to get access

Abstract

Background

Storage lower urinary tract symptoms (LUTS) including overactive bladder (OAB) and urinary incontinence (UI) affect millions of people worldwide, significantly impacting quality of life. Plant based medicines have been documented both empirically and in emerging scientific research to have varying benefits in reducing bladder symptoms. We assessed the efficacy of Urox®, a proprietary combination of phytomedicine extracts including, Cratevox™ (Crataeva nurvala) stem bark, Equisetem arvense stem and Lindera aggregata root, in reducing symptoms of OAB and UI.

Methods

Efficacy of the herbal combination on a variety of bladder symptoms compared to an identical placebo, were documented in a randomised, double-blind, placebo controlled trial conducted at two primary care centres. Data were collected at baseline, 2, 4 and 8 weeks, with the primary outcome being self-reported urinary frequency. Statistical analysis included mixed effects ordered logistic regression with post hoc Holm’s test to account for repeated measures, and included an intention-to-treat analysis.

Results

One hundred and fifty participants (59% female, aged; mean ± SD; 63.5 ± 13.1 years) took part in the study. At week 8, urinary day frequency was significantly lower (OR 0.01; 95%CI 0.01 to 0.02; p < 0.001) in response to treatment (mean ± SD; 7.69 ± 2.15/day) compared to placebo (10.95 ± 2.47/day). Similarly, episodes of nocturia were significantly fewer (OR 0.03; 95%CI 0.02 to 0.05) after 8 weeks of treatment (2.16 ± 1.49/night) versus placebo (3.14 ± 1.36/night). Symptoms of urgency (OR 0.02; 95%CI 0.01 to 0.03), and total incontinence (OR 0.03; 95% CI 0.01 to 0.06) were also lower (all p < 0.01) in the treatment group. Significant improvements in quality of life were reported after treatment in comparison to placebo. No significant side effects were observed resulting in withdrawal from treatment.

Conclusions

The outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of OAB, urinary frequency and/or urgency and incontinence. The demonstrated viability of the herbal combination to serve as an effective treatment, with minimal side-effects, warrants further longer term research and consideration by clinicians.

Trial registration

NCT02396160 (registered on 17 March 2015 - before any statistical analyses commenced).
Literature
1.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003;61(1):37–49.CrossRefPubMed
2.
3.
Culligan P, Sand P. Involuntary urine loss in women: help for a hidden problem. Patient Care. 1998;32(2):141–62.
4.
Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010;75(3):491–501.CrossRefPubMed
5.
6.
Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R, Hunt T, Wein A. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.PubMed
7.
Irwin D, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschom S, Coyne K, Kelleher C, Hampel C, Artibani W, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14.CrossRefPubMed
8.
CDC. US toll from incontinence. JAMA. 2014;312(9):884.
9.
10.
Hann-Chorng K. Male lower urinary tract symptoms - an old problem from a new perspective. Incont Pelvic Floor Dysfunct. 2010;4(2):33–8.
11.
Chun-Hou L, Hann-Chorng K. Measurement of international prostate symptom score subscores in male lower urinary tract symptoms. Incont Pelvic Floor Dysfunct. 2010;4(2):39–43.
12.
Chutka D, Fleming K, Evans M, Evans J, Andrews K. Urinary incontinence in the elderly population. Mayo Clin Proc. 1996;71(1):93–101.CrossRefPubMed
13.
Peake S, Manderson L, Potts H. Part and parcel of being a woman: female urinary incontinence and constructions of control. Med Anthropol Q. 1999;13(3):267–85.CrossRefPubMed
14.
Rane A. Incontinence in women. Don’t suffer it. Aust Fam Physician. 1999;28(6):584–6.PubMed
15.
Chiarelli P, Brown W. Leaking urine in Australian women: prevalence and associated conditions. Womens Health. 1999;29(1):1–13.CrossRef
16.
Herschorn S, Jones J, Oelke M, MacDiarmid S, Wang J, Guan Z. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology. 2010;75(5):1149–55.CrossRefPubMed
17.
Madhuvrata P, Cody J, Ellis G, Herbison G, Hay-Smith E. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429.
18.
Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent). 2007;20(3):307–14.CrossRef
19.
Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.CrossRefPubMed
20.
Getsios D, Caro J, Ishak K, El-Hadi W, Payne K, O'Connel M, Albrecht D, Feng W, Dubois D. Oxybutynin extended release and Tolterodine immediate release: a health economic comparison. Clin Drug Investig. 2004;24(2):81–8.CrossRefPubMed
21.
Gray S, Anderson M, Dublin S, Hanlon J, Hubbard R, Walker R, Yu O, Crane P, Larson E. Cumulative use of strong anticholinergics and incident dementia. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedPubMedCentral
22.
Fox C, Richardson K, Maidment I. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–83.CrossRefPubMed
23.
Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013;9(4):377–85.CrossRefPubMed
24.
Shamliyan T, Wyman J, Ramakrishnan R, Sainfort F, Kane R. Benefits and harms of pharmacologic treatment for urinary incontinence in women. Ann Intern Med. 2012;156(12):861–74.CrossRefPubMed
25.
Bensky D, Gamble A. Chinese herbal: Materia Medica, revised edn. Seattle: Eastland Press Inc.; 1993.
26.
Bone K. Clinical applications of Ayurvedic and Chinese herbs; monographs for the western herbal practitioner. Warick: Phytotherapy Press; 1997.
27.
BHP: British Herbal Pharmacopeia. 1983. Published by The Bristish Herbal Association, Lane House, Cowling, Nr. Keighley, West Yorks.
28.
Deshpande P, Sahu M, Kumar P. Crataeva nurvala hook and Forst (Varuna) the Ayurvedic drug of choice in urinary disorders. Indian J Med Res. 1982;76((suppl) December):46–53.PubMed
29.
30.
Nadkarni KM. Indian Materia Medica. Bombay: Bombay Popular Prakashan; 1976.
31.
Anand R, Patnaik GK, Roy K, Bhaduri AP. Antixoaluric and anticalciuric activity. Indian J Pharmacol. 1995;27(4):265–8.
32.
Varalakshmi P, Shamila Y, Latha E. Effect of Crataeva Nurvala in experimental urolithiasis. J Ethnopharmacol. 1990;28:313–21.CrossRefPubMed
33.
Malini M, Ramakrishnan B, Varalakshmi P. Effet of Lupeol, a pentacyclic triterpene, on urinary enzymes in hyperoaluric rats. Jpn J Med Sci Biol. 1995;48:211–20.CrossRefPubMed
34.
Geetha T, Varalakshmi P. Anti-inflammatory activity of lupeol and lupeol linoleate in rats. J Ethnopharmacol. 2001;76:77–80.CrossRefPubMed
35.
Geetha T, Varalakshmi P. Anticomplement activity of triterpenes from Crataeva nurvala stem bark in adjuvant arthritis in rats. Gen Pharmacol. 1999;32:495–7.CrossRefPubMed
36.
Council AB. Horsetail herb. In: Expanded commission E monograph; 2000.
37.
Grases F, Melero G, Costa-Bauza A, Prieto R, March JG. Urolithiasis and phytotherapy. Int Urol Nephrol. 1994;26(5):507–11.CrossRefPubMed
38.
Nagao A, Seike M, Kobayashi H. Inihibition of xanthine oxidase by flaonoids. Biosci Biotechnol Biochem. 1999;63(10):1787–90.CrossRefPubMed
39.
Steels E, Ryan J, Seipel T, Rao A. Crataeva and equisetum reduce urinary incontinence symptoms. Aust Continence J. 2002;8(3):46–50.
40.
Schauss A, Steele E. Preliminary evidence of the safety and efficacy of urologic™, an herbal formulation for the treatment of urinary incontinence and overactive bladder. FASEB. 2006;20:A990.
41.
Norton P, Karram M, Wall L, Resenzeig B, Benson U, Fantl J. Randomised double-blind trial of terodiline in the treatment of urge incontinence in women. Obstet Gynecol. 1994;84(3):386–91.PubMed
42.
Wyman J, Choi S, Harkins S, Wilson M, Fantl J. The urinary diary in evaluation of urinary incontinence in women: a test-retest analysis. Obstet Gynecol. 1988;71(6 Pt 1):812–7.PubMed
43.
Nygaard I, Holcomb R. Reproducibility of the seven-day in women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):15–7.CrossRefPubMed
44.
Coyne K, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. Br J Urol Int. 2003;92(7):731–5.CrossRef
45.
Robinson J, Shea J. Development and testing of a measure of health-related quality of life for men with urinary incontinence. J Am Geriatr Soc. 2002;50(5):335–45.CrossRef
46.
Coyne K, Revicke D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563–74.CrossRefPubMed
47.
Matza L, Thompson C, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne K. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24(3):215–25.CrossRefPubMed
48.
Shim B, Jeong H, Lee S, Hwang S, Moon B, Storni C. A randomized double-blind placebo-controlled clinical trial of a product containing pumpkin seed extract and soy germ extract to improve overactive bladder-related voiding dysfunction and quality of life. J Funct Foods. 2014;8c:111–7.CrossRef
49.
Sigurdsson S, Geirsson G, Gudmundsdottir H, Egilsdottir P, Gudbvjarnason S. A parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men. Scand J Urol. 2013;47(1):26–32.CrossRefPubMed
50.
Vidlar A, Vostalova J, Ulrichova J, Student V, Stejskal D, Reichenback R, Vrbkova J, Ruzicka F, Simanek V. The effectiveness of dried cranberries (Vaccinium Macrocarpon) in men with lower urinary tract symptoms. Br J Nutr. 2010;104(8):1181–9.CrossRefPubMed
Metadata
Title
Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial
Authors
Niikee Schoendorfer
Nita Sharp
Tracey Seipel
Alexander G. Schauss
Kiran D. K. Ahuja
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2018
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-018-2101-4

Other articles of this Issue 1/2018

BMC Complementary Medicine and Therapies 1/2018 Go to the issue

Research article

Effect of Moringa oleifera consumption on diabetic rats

Correction

Correction to: Inhibition of autophagy enhances synergistic effects of Salidroside and anti-tumor agents against colorectal cancer

Research article

Antimicrobial and antioxidant activities of triterpenoid and phenolic derivatives from two Cameroonian Melastomataceae plants: Dissotis senegambiensis and Amphiblemma monticola

Research article

Stakeholder expectations from the integration of chiropractic care into a rehabilitation setting: a qualitative study

Research article

Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials

Research article

Antioxidant and skin-whitening effects of aerial part of Euphorbia supina Raf. Extract